8-K: Biodesix Soars on Strong Q3, Raises 2025 Revenue Outlook

Biodesix, Inc. reported a robust third quarter with 20% revenue growth and improved gross margins, leading to an increased full-year 2025 revenue guidance.

Summary

• Total revenue for Q3 2025 was $21.8 million, marking a 20% increase over Q3 2024.
• Lung Diagnostic Testing revenue reached $19.8 million in Q3 2025, up 16% from the prior year, driven by increased tests and average revenue per test.
• Development Services revenue grew 97% year-over-year to $1.9 million in Q3 2025, due to delivering on contracted business and securing new agreements.
• Gross profit margin improved by 400-basis points to 81% in Q3 2025, totaling $17.7 million.
• Net loss for Q3 2025 was $8.7 million, an improvement of 15% compared to Q3 2024.
• Adjusted EBITDA was a loss of $4.6 million for Q3 2025, an 18% improvement over Q3 2024.
• Cash and cash equivalents stood at $16.6 million as of September 30, 2025, a decrease of $4.1 million from June 30, 2025.
• The company raised its FY2025 total revenue guidance to $84-86 million.
• Lung Diagnostic Tests ordered in primary care increased by more than 75% during the quarter compared to Q3 2024.
• Development Services business reported $12.9 million in dollars under contract, up 16% year-over-year.

Sentiment

Score: 8

Explanation: The company reported strong Q3 financial results with significant revenue growth and improved margins, leading to an upward revision of full-year revenue guidance and a projection for Adjusted EBITDA positivity in Q4. This indicates strong operational momentum and positive future prospects.

Positives

• Total revenue increased 20% to $21.8 million in Q3 2025 compared to Q3 2024.
• Gross profit margin improved by 400-basis points to 81% in Q3 2025.
• Development Services revenue grew 97% year-over-year to $1.9 million.
• Net loss improved by 15% to $8.7 million in Q3 2025.
• Adjusted EBITDA loss improved by 18% to $4.6 million in Q3 2025.
• FY2025 total revenue guidance was raised to $84-86 million.
• Lung Diagnostic Tests ordered in primary care increased by over 75% year-over-year.
• Development Services business reported $12.9 million in dollars under contract, up 16% year-over-year.
• The company expects to achieve Adjusted EBITDA positivity in Q4 2025.
• A major Medicare Advantage plan restarted paying current claims, contributing to Lung Diagnostic Testing revenue growth.

Negatives

• The company still reported a net loss of $8.7 million in Q3 2025.
• Adjusted EBITDA remained a loss of $4.6 million in Q3 2025.
• Cash and cash equivalents decreased by $4.1 million from June 30, 2025, to $16.6 million as of September 30, 2025.
• Accounts receivable increased by $5.2 million, primarily due to higher revenue and the timing of cash receipts.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from projections.
• Risks include the impact of backlog and the timing and assumptions regarding the collection of revenues on projections.
• The availability of funds and future capital, including under the term loan facility, poses a risk.
• The anticipated impact and benefits of new clinical data, reimbursement coverage, and research partnerships may not materialize as expected.
• There is a risk that common stock may not maintain compliance with the minimum bid price requirement or other applicable listing standards of The Nasdaq Stock Market LLC.
• The impact of enhanced U.S. tariffs, import/export restrictions, or other trade barriers on operations and financial performance is a risk.

Future Outlook

The company raised its 2025 revenue guidance to $84-86 million, citing strong Q3 performance and ongoing momentum. Management expects to achieve Adjusted EBITDA positivity in the fourth quarter of 2025, driven by a growing commercial organization, expanding market reach, and operational excellence, positioning Biodesix for sustainable long-term growth.

Management Comments

• "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year." Scott Hutton, CEO.
• "Our strategic expansion into primary care is proving to be additive, demonstrating our ability to drive adoption in pulmonology while also partnering with them to drive upstream testing in their referral network." Scott Hutton, CEO.
• "Our Development Services business continues to accelerate with 97% year-over-year growth and another quarter ending with a record number of dollars under contract." Scott Hutton, CEO.
• "With our growing commercial organization and with the sustained positive momentum across both business units, we are well-positioned to achieve Adjusted EBITDA positivity in the fourth quarter." Scott Hutton, CEO.
• "We believe the combination of our proven diagnostic solutions, expanding market reach, and operational excellence positions Biodesix for sustainable long-term growth as we continue to improve outcomes for patients with lung disease." Scott Hutton, CEO.
• "Based on how we closed the third quarter and the ongoing momentum into the fourth quarter, we are increasing our revenue guidance for 2025 to $84-86 million." Scott Hutton, CEO.

Industry Context

Biodesix operates in the diagnostic solutions industry, specializing in lung disease diagnostics. The company's strategic expansion into primary care and the acceleration of its Development Services business align with broader industry trends towards precision medicine, early disease detection, and outsourced R&D for biopharmaceutical companies. The strong growth in Development Services indicates a robust demand for specialized diagnostic test development capabilities within the life sciences sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks or industry standards.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, raised revenue guidance, and anticipated Adjusted EBITDA positivity, which could lead to increased share value.
• Patients with lung disease benefit from improved clinical care and outcomes through Biodesix Diagnostic Tests like Nodify Lung and IQLung.
• Employees are positively impacted by the planned expansion of the sales team to support growth.
• Biopharmaceutical, life sciences, and research institutions benefit from the acceleration of Development Services, securing new agreements and delivering against contracted business.
• Payer coverage providers, such as Medicare Advantage plans, are engaged through continued claim payments for diagnostic tests.

Next Steps

• Host a conference call and webcast on November 3, 2025, at 4:30 p.m. ET to discuss the results.
• Conduct an R&D Corporate Workshop at the Association for Molecular Pathology (AMP) Annual Meeting on November 12, 2025, at 4:00 pm ET, focusing on R&D efforts, pipeline, and partnerships.
• Continue the strategic expansion of the commercial organization and market reach.
• Persist in efforts to improve outcomes for patients with lung disease.

Key Dates

Recommendation

The company demonstrated robust Q3 performance with significant revenue growth across both diagnostic testing and development services, coupled with substantial gross margin improvement and a notable reduction in net loss and Adjusted EBITDA loss. The upward revision of full-year revenue guidance and the explicit expectation of achieving Adjusted EBITDA positivity in Q4 2025 signal strong operational momentum and a clear path towards profitability. Strategic expansion into primary care and accelerating development services indicate sustainable growth drivers. While cash decreased, it was partially offset by an at-the-market offering, and the increase in accounts receivable is tied to higher revenue, with collections expected in Q4. These factors collectively present a compelling investment case for strong future performance.

Keywords

Biodesix, BDSX, diagnostic solutions, lung disease, Nodify Lung, IQLung, Q3 2025 results, revenue guidance, Adjusted EBITDA, primary care, development services, molecular diagnostics, SEC filing, 8-K